Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of symptoms associated with uterine fibroids and endometriosis. It is administered orally, at a dose of 100 to 200 mg per day, usually in combination with oestradiol and norethisterone.
As of the last update, no information is available on the use of linzagolix during breastfeeding.
Its pharmacokinetic data (moderately high molecular weight and very high plasma protein binding) make it unlikely that clinically significant amounts will pass into breast milk.
Until further published data on this drug in relation to breastfeeding become available, known safer alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
As milk production depends on minimum levels of oestrogen, this product could theoretically reduce milk production.
Translated with DeepL.com (free version)
See below the information of these related products: